<table>
<thead>
<tr>
<th>Highlights of This Issue</th>
<th>5839</th>
</tr>
</thead>
</table>

**SPECIAL FEATURES**

<table>
<thead>
<tr>
<th>CCR Translations</th>
<th>5841</th>
</tr>
</thead>
<tbody>
<tr>
<td>Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma</td>
<td>Michael R. Harrison and Daniel J. George</td>
</tr>
<tr>
<td>See article p. 6021</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Molecular Pathways</th>
<th>5844</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone</td>
<td>James L. Mohler, Mark A. Titus, and Elizabeth M. Wilson</td>
</tr>
<tr>
<td>ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease</td>
<td>Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huei-Chi Wen, and Julio A. Aguirre-Ghiso</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Review</th>
<th>5858</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombotic Microangiopathy with Targeted Cancer Agents</td>
<td>John A. Blake-Haskins, Robert J. Lechleider, and Robert J. Kreitman</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HUMAN CANCER BIOLOGY</th>
<th>5867</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CANCER THERAPY: PRECLINICAL</th>
<th>5901</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma</td>
<td>Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalo Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>5913</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th>5926</th>
</tr>
</thead>
<tbody>
<tr>
<td>Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody</td>
<td>Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan</td>
</tr>
</tbody>
</table>

| Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance | Kelly M. Quesnelle and Jennifer R. Grandis |
Targeting Human B-cell Malignancies through Ig Light Chain–Specific Cytotoxic T Lymphocytes
Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Gheath Alatrasch, Michael S. Popescu, Qing Yi, Jeffrey J. Mollrrem, Michael Wang, Satvva S. Neelapu, and Larry W. Kwak

Curcumin Treatment Suppresses IKKβ Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study
Suejung G. Kim, Mysore S. Veena, Saroj K. Basak, Eugene Han, Tracey Tajima, David W. Gjertson, Joshua Starr, Ofer Eidelman, Harvey B. Pollard, Meera Srivastava, Eri S. Srivatsan, and Marilene B. Wang

Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjærgaard Jørgensen, Adam Hey, and Michael Kragh

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bel-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents
Cyrille Touzeau, Christelle Dousset, Linda Bodet, Patricia Gomez-Bougie, Stéphanie Bonnass, Anne Moreau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot, and Steven Le Gouill
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

About the Cover
Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models. In addition, high plasma IL-6 levels are associated with poor prognosis in ovarian cancer, but there is little information as to the source of this IL-6. Ovarian cancer biopsies were stained for IL-6 (left) and automated algorithms used to assess both malignant (right) and stromal (middle) compartments. Expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in both the malignant and nonmalignant cells, but was significantly higher in the malignant cell areas. For further details, see Coward and colleagues on page 6083 of this issue.